Caris Life Sciences (CAI) Revenue & Revenue Breakdown
Caris Life Sciences Revenue Highlights
Latest Revenue (Y)
$294.01M
Latest Revenue (Q)
$216.83M
Caris Life Sciences Revenue by Period
Caris Life Sciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2020-12-31 | $294.01M | -29.42% |
| 2019-12-31 | $416.54M | -3.60% |
| 2018-12-31 | $432.10M | 24.03% |
| 2017-12-31 | $348.39M | 18.36% |
| 2016-12-31 | $294.35M | 17.90% |
| 2015-12-31 | $249.67M | 9.70% |
| 2014-12-31 | $227.59M | 7.15% |
| 2013-12-31 | $212.41M | 22.12% |
| 2012-12-31 | $173.93M | 38.36% |
| 2011-12-31 | $125.71M | 61.37% |
| 2010-12-31 | $77.90M | 19.36% |
| 2009-12-31 | $65.26M | -21.51% |
| 2008-12-31 | $83.14M | 28.17% |
| 2007-12-31 | $64.87M | 248.57% |
| 2006-12-31 | $18.61M | - |
Caris Life Sciences generated $294.01M in revenue during NA 2020, up -29.42% compared to the previous quarter, and up 117.76% compared to the same period a year ago.
Caris Life Sciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $216.83M | 19.53% |
| 2025-06-30 | $181.40M | 50.02% |
| 2025-03-31 | $120.92M | 20.86% |
| 2024-06-30 | $100.05M | 24.01% |
| 2024-03-31 | $80.68M | -19.98% |
| 2021-09-30 | $100.83M | 17.66% |
| 2021-06-30 | $85.69M | 6.06% |
| 2021-03-31 | $80.80M | 25.62% |
| 2020-12-31 | $64.32M | -18.64% |
| 2020-09-30 | $79.05M | 4.39% |
| 2020-06-30 | $75.72M | -27.90% |
| 2020-03-31 | $105.02M | 4.85% |
| 2019-12-31 | $100.17M | -6.88% |
| 2019-09-30 | $107.57M | 1.89% |
| 2019-06-30 | $105.58M | -4.98% |
| 2019-03-31 | $111.11M | -3.86% |
| 2018-12-31 | $115.57M | 0.10% |
| 2018-09-30 | $115.45M | 9.22% |
| 2018-06-30 | $105.70M | 10.83% |
| 2018-03-31 | $95.37M | 1.43% |
| 2017-12-31 | $94.03M | 4.30% |
| 2017-09-30 | $90.16M | 9.03% |
| 2017-06-30 | $82.69M | 1.46% |
| 2017-03-31 | $81.51M | 5.48% |
| 2016-12-31 | $77.27M | -1.53% |
| 2016-09-30 | $78.47M | 9.53% |
| 2016-06-30 | $71.64M | 6.98% |
| 2016-03-31 | $66.97M | 1.94% |
| 2015-12-31 | $65.69M | -0.64% |
| 2015-09-30 | $66.12M | 11.37% |
| 2015-06-30 | $59.37M | 1.49% |
| 2015-03-31 | $58.49M | -0.54% |
| 2014-12-31 | $58.81M | -0.66% |
| 2014-09-30 | $59.20M | 7.03% |
| 2014-06-30 | $55.31M | 1.93% |
| 2014-03-31 | $54.26M | -0.54% |
| 2013-12-31 | $54.56M | 1.23% |
| 2013-09-30 | $53.90M | 1.72% |
| 2013-06-30 | $52.99M | 3.98% |
| 2013-03-31 | $50.96M | 2.22% |
| 2012-12-31 | $49.85M | 10.94% |
| 2012-09-30 | $44.94M | 17.93% |
| 2012-06-30 | $38.11M | 0.43% |
| 2012-03-31 | $37.94M | 4.69% |
| 2011-12-31 | $36.24M | 9.95% |
| 2011-09-30 | $32.96M | 14.61% |
| 2011-06-30 | $28.76M | 3.67% |
| 2011-03-31 | $27.74M | 9.98% |
| 2010-12-31 | $25.22M | 25.37% |
| 2010-09-30 | $20.12M | 15.87% |
| 2010-06-30 | $17.36M | 14.28% |
| 2010-03-31 | $15.19M | -0.82% |
| 2009-12-31 | $15.32M | -2.49% |
| 2009-09-30 | $15.71M | -5.71% |
| 2009-06-30 | $16.66M | -5.21% |
| 2009-03-31 | $17.58M | -22.67% |
| 2008-12-31 | $22.73M | 2.73% |
| 2008-09-30 | $22.12M | 7.18% |
| 2008-06-30 | $20.64M | 16.95% |
| 2008-03-31 | $17.65M | -6.46% |
| 2007-12-31 | $18.87M | 8.11% |
| 2007-09-30 | $17.45M | 24.38% |
| 2007-06-30 | $14.03M | -3.30% |
| 2007-03-31 | $14.51M | -161.92% |
| 2006-12-31 | $-23.44M | - |
Caris Life Sciences generated $216.83M in revenue during Q3 2025, up 19.53% compared to the previous quarter, and up 215.05% compared to the same period a year ago.
Caris Life Sciences Revenue Breakdown
Caris Life Sciences Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 25 | Jun 25 |
|---|---|---|
| Pharma Research And Development Services | $9.25M | $18.47M |
Latest
Caris Life Sciences's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Pharma Research And Development Services (100.00%).
Caris Life Sciences Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Sep 25 | Jun 25 |
|---|---|---|
| Non-US | $3.28M | $3.22M |
| UNITED STATES | $213.55M | $178.18M |
Latest
Caris Life Sciences's latest quarterly revenue breakdown by geography, as of Sep 25: UNITED STATES (98.49%), and Non-US (1.51%).
Caris Life Sciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals | $4.07B | $1.05B |
| MRNA | Moderna | $3.24B | $1.02B |
| HALO | Halozyme Therapeutics | $1.02B | $354.26M |
| CORT | Corcept Therapeutics | $675.04M | $207.64M |
| CAI | Caris Life Sciences | $294.01M | $216.83M |
| MDGL | Madrigal Pharmaceuticals | $180.13M | $287.27M |
| RYTM | Rhythm Pharmaceuticals | $130.13M | $51.30M |
| MRUS | Merus | $36.13M | $12.15M |
| CYTK | Cytokinetics | $18.47M | $66.77M |
| RNA | Avidity Biosciences | $10.90M | $12.47M |
| ABVX | Abivax | - | - |